Open AccessThe shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective
Author(s) -
Fatima Saeeda,
Jameel Ayesha,
Ayesha FNU,
Menzies Dhananjai J.
Publication year - 2017
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.22781
Subject(s) - medicine , metformin , type 2 diabetes mellitus , diabetes mellitus , dipeptidyl peptidase 4 , glucagon like peptide 1 , intensive care medicine , type 2 diabetes , multitude , endocrinology , philosophy , epistemology
In patients with diabetes mellitus, cardiovascular (CV) disease is the leading cause of morbidity and mortality. A multitude of contemporary antidiabetic agents presents different CV safety profiles. Metformin forms the cornerstone agent to reduce CV events. Newer agents, such as glucagon‐like peptide‐1 agonists and sodium‐glucose cotransporter‐2 inhibitors, have appealing CV benefits. Insulin, dipeptidyl peptidase‐4 inhibitors, and sulfonylureas have neutral CV effects. Cardiologists should familiarize themselves with these agents to promote comprehensive CV care in patients with diabetes mellitus.